Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ
Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ
向80億美元的德國市場進行輕資產擴張增加了納斯達克這隻大麻股票的潛力
The potential rescheduling of cannabis in the U.S. and the growing demand in Germany positions InterCure (NASDAQ:INCR), the leading seller of pharmaceutical cannabis outside North America, to capitalize on these opportunities, according to a recent initiation note by Pablo Zuanic of Zuanic & Associates.
根據Zuanic & Associates的Pablo Zuanic最近發佈的啓動報告，美國可能重新安排大麻的期限以及德國需求的增長，使北美以外主要的藥用大麻銷售商InterCure（納斯達克股票代碼：INCR）有能力抓住這些機會。
Zuanic highlighted said that "InterCure's experience in Israel, a market five years ahead of Germany in development, gives it a competitive edge." He also noted that "down the road, INCR could enter the U.S. market if FDA-approved and controlled pharmaceutical cannabis is federally legalized. In a global industry context, InterCure has...
祖安尼奇強調說：“InterCure在以色列的市場發展比德國領先五年，其經驗使其具有競爭優勢。”他還指出，“...
登入免費觀看全文
登入/註冊